Article and Video CATEGORIES
Dr. Ravi Salgia on Management Strategies for Acquired Resistance to Targeted Therapies, Single Focus or More Diffuse
Dr. Ravi Salgia from University of Chicago explains his approach to management of acquired resistance to a targeted therapy for advanced NSCLC, both in the setting of a single area of progression and also when disease progression is more diffuse.
[powerpress]
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Video
The 2024 Lung Cancer OncTalk was a live, virtual, interactive patient education event presented in December 2024, moderated by Dr. Ibiayi Dagogo-Jack, Assistant Professor of Medicine at Harvard Medical School and a Medical Oncologist at Massachusetts General Hospital, and joined by speakers: Dr. Misty Shields, Indiana University School of Medicine, Dr. Alissa Cooper, Memorial Sloan Kettering Cancer Center, Dr. Angel Qin, University of Michigan Rogel Cancer Center, and Dr. Julia Rotow, Harvard Medical School.
Topics include:
Image
Video
This event was moderated by Dr. Sridevi Rajeeve, Memorial Sloan Kettering, joined by speakers: Dr. Hamza Hashmi, Memorial Sloan Kettering, Dr. Michele Stanchina, University of Miami, Dr. Muhammad Salman Faisal, Oklahoma University, and Dr. Andrew Srisuwananukorn, Ohio State University
Topics include:
- Myeloma 101: Facts and Fiction of the 'Myeloma Marathon'
- Updates in DLBCL
- Treatment Basics of Bone Marrow Transplant
- Frontline Therapies in Myelofibrosis
- Panel Discussions and a Question-and-Answer session
Forum Discussions
Hi Stan,
It's so good to hear you and yours are doing well and that you were able to spend time with both families for Thanksgiving. I know it meant a...
Hi Stan! It is good to hear from you -- I am so very happy you are doing well. I agree with Janine that family and friends - our chosen family...